The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
Blood Cell Transplant

A-Z Index  |  Questions? 

  • Print this
  • Email this

Glossary for the U.S. Transplant Data by Disease Report

Cell Source 

Where the blood-forming cells used for transplant are collected from.

  • Bone marrow, the soft spongy tissue found inside of bones, produces blood-forming cells for the body. The bone marrow for a transplant is collected from a donor's pelvic bone during a surgical procedure in a hospital.
  • Peripheral blood stem cells (PBSC) are found circulating in the bloodstream. Normally, the bone marrow releases a small number of blood-forming cells into the bloodstream. A donor receives injections of a medication that increases the number of blood-forming cells in the blood. Then, the donor's blood is collected in a non-surgical procedure done in an outpatient clinic.
  • Umbilical cord blood contains a large number of blood-forming cells. Cord blood is collected from the umbilical cord and placenta in a hospital after a baby is born.

Disease Status 

A measure of how the disease responded to treatment before the patient received a bone marrow or umbilical cord blood transplant. The disease status can help predict the likelihood of a better or worse survival outcome after transplantation.

In these reports, disease status is included only for leukemias, lymphomas and multiple myeloma. Disease status are categorized as:

  • In remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • Not in remission—The disease is not responding to treatment. There is still evidence of leukemia.
  • No data—The disease status was not available.

Donor Type 

Biological relationship between the patient and the donor who provided the blood-forming cells.

  • Autologous—The patient's own cells were collected, stored and infused back into the patient.
  • Allogeneic—Another person donated bone marrow, peripheral blood, or an umbilical cord blood unit. These cells match the patient’s human leukocyte antigen (HLA) type. Specific allogeneic types include:
    • HLA-identical sibling—The brother or sister who donated cells is the patient's biological sibling who matches the patient’s HLA type.
    • HLA-identical twin – The brother or sister who donated cells is the patient’s monozygotic twin who shares the patient’s DNA.
    • Other related donor—The family member who donated cells is related biologically to the patient and is not included in the HLA-matched sibling or identical twin category. The donor might have variable degrees of mismatch to the patient.
    • Unrelated—The person who donated cells is not biologically related to the patient.

Human Leukocyte Antigen (HLA) 

Proteins on cells that make each person's tissue type, which varies from person to person.

HLA typing is used to match patients and donors for a bone marrow or umbilical cord blood transplant. A person's HLA type is identified by testing a blood sample or swab of cheek cells.

Patient Age 

Age of a patient at the time of a bone marrow or umbilical cord blood transplant. These reports provide the age in 10-year intervals.
“Unknown” means the age was not reported.

Patient Gender 

The sex of a patient: male or female.
“Unknown” means the gender was not reported.

Patient Race 

Race or ethnicity of a patient. These reports have only two categories:

  • White
  • Black or African American
  • Asian
  • American Indian or Alaska Native
  • Native Hawaiian or Other Pacific Islander

Survival Probability Estimate 

The best estimate of the chance that a person will be alive at a specified time after transplant. This estimate is based on the data reported. View an example.

Learning About Statistics